Segment Disclosure

12 Months Ended

Jun. 30, 2018

Note 15. Segment Disclosure

The Company has one operating and reporting segment (oncology systems group), which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients. The Company’s Chief Executive Officer, its Chief Operating Decision Maker, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance. The Company does not assess the performance of its individual product lines on measures of profit or loss, or asset based metrics. Therefore, the information below is presented only for revenues and long‑lived tangible assets by geographic areas.

Revenues attributed to a country or region is based on the shipping addresses of the Company’s customers. The following summarizes revenue by geographic region (in thousands):

	Years ended June 30,
	2018		2017		2016
Americas	$	145,689	$	151,442	$	159,517
Europe, Middle East, India and Africa		120,032		104,026		138,877
Asia Pacific		72,925		59,278		62,888
Japan		66,251		68,668		37,518
Total	$	404,897	$	383,414	$	398,800

Information regarding geographic areas in which the Company has long‑lived tangible assets is as follows (in thousands):

	June 30, 2018		June 30, 2017
Americas	$	19,698	$	18,435
Europe, Middle East, India and Africa		569		730
Asia Pacific (excluding Japan and India)		1,635		1,533
Japan		1,796		2,364
Total	$	23,698	$	23,062